Skip to main content
OpenTrials
Completed

NCT Number: NCT01487993

Metformin in Obese Children and Adolescents

The purpose of this study is to determine whether metformin is effective in reducing BMI and insulin resistance in obese children and adolescents.

Completed

Looking for future studies?

Notify Me

Key information

Age range

10 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands

Loading trial locations.

About this study

The prevalence of obesity in children and adolescents is increasing rapidly and is associated with significant medical and psychosocial consequences persisting into adulthood.

Obesity may lead to metabolic complications, such as insulin resistance, which can progress via impaired fasted glucose and impaired glucose tolerance to type 2 diabetes mellitus (T2DM) and to the development of micro- and macro-vascular complications.

Metformin, an oral anti-diabetic licensed for T2DM for adults and children from 10 years onwards, is already used off label in obese children and adolescents with insulin resistance, even though the specific effects of metformin in these obese children and adolescents have not been elucidated, particularly upon long-term use.

The rationale for this study is based on the hypothesis that metformin may reduce body mass index (BMI), insulin resistance and percentage of body-fat in obese children and adolescents with insulin resistance. Further more it is anticipated that metformin may delay the progression to T2DM and thereby micro- and macro-vascular complications in obese children and adolescents with insulin resistance.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 10 and ≤ 16 years at study entry
  • Caucasian descent
  • Obesity defined as BMI-SDS > 2.3
  • Insulin resistance defined as HOMA-IR ≥ 3.4.
  • An obtained informed consent from subjects and parents/caregivers.

Exclusion criteria

  • Presence of T2DM (American Diabetes Association criteria)
  • Presence of endocrine disorders with steroid therapy
  • Suspicion of polycystic ovarium syndrome;
  • Height < -1.3 SD of target height;
  • Syndrome disorders with or without mental retardation;
  • Use of anti-hyperglycaemic drugs;
  • Pregnancy (pregnancy test will be performed, if applicable);
  • (History of) alcohol abuse;
  • Impaired renal and/or hepatic function (defined as GFR < 80 ml/min. GFR=40 x length (cm) / serumcreatinin (μmol/l and ALAT >150% of normal value for age);
  • Use of ritonavir; use of ACE inhibitors;
  • Insufficient knowledge of the Dutch language.

Treatment and study plan

metformin

Drug

Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.

Other names: Glucophage

Lifestyle Intervention

Behavioral

Lifestyle intervention: 18 months physical therapy and dietary advice

Primary outcomes

  1. Change in BMI from baseline

    Time frame: 18 months and 36 months

    Change in BMI after part 1 (double blind) and part 2 ( follow-up)

  2. Change in Insulin resistance from baseline

    Time frame: 3; 6; 9; 12; 15; 18; 24; 30 and 36 months

    calculated by the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR).

Secondary outcomes

  1. Renal and hepatic function

    Time frame: 3; 6; 9; 12; 15; 18; 24; 30 and 36 months

    creatinine and alat

  2. Tolerability

    Time frame: 3; 6; 9; 12; 15; 18; 24; 30 and 36 months

    The amount of reported adverse effects, in relation to the achieved dose level.

  3. Pharmacokinetics (PK)-parameters: clearance (ml/min)

    Time frame: 9 months

    Clearance where applicable expressed per body weight, age category, Tanner Stage and gender, clearance will be determined with a two-compartment pharmacokinetic model using non linear mixed effect modelling.

  4. Body fat percentage

    Time frame: 0, 9, 18 and 36 months

  5. Physical fitness

    Time frame: 0, 9, 18 and 36 months

  6. Quality of life

    Time frame: 0, 9, 18 and 36 months

  7. Long term efficacy

    Time frame: 36 months

    Based on BMI and HOMA-IR values

  8. Long-term safety

    Time frame: 36 months

    Renal and hepatic function after 36 months of metformin use

  9. Long-term tolerability

    Time frame: 36 months

    The amount of adverse effects after 36 months

  10. Microvascular complications

    Time frame: 36 months

    Measured as micro-albuminuria

  11. Macrovascular complications

    Time frame: 36 monthts

    Measured with Pulse Wave Velocity and Augmentation Index.

  12. Development of T2DM

    Time frame: 36 months

  13. PK-parameters: volume of distribution (liters)

    Time frame: 9 months

    Volume of distribution, where applicable expressed per body weight, age category, Tanner Stage and gender, volume of distribution will be determined with a two-compartment pharmacokinetic model using non linear mixed effect modelling.

Sponsors and collaborators

Lead sponsor

St. Antonius Hospital

Other

Collaborators

  • Jeroen Bosch Ziekenhuis

Registry information

Official study title

An Efficacy, Safety and Pharmacokinetic Study on the Short-term and Long-term Use of Metformin in Obese Children and Adolescents

Acronym: MetVoorMin

Important dates

Study start
2011
Primary completion
2015
Study completion
2017
First posted
Dec 8, 2011
Registry last updated
Apr 27, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.